16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Autor:	T.C. Hernandez Guerrero, Ana Rita Martins Pinto, R. Sarmiento, Marlene Zuraek, G. Musuraca, B. Hanna, Bernard Doger, J-M. Michot, J. De Alvaro, I. Aronchik, T. Sánchez-Pérez, J.M. Sepulveda Sanchez, C. Carlo Stella, O. Saavedra, Victor Moreno, Irene Brana, Zariana Nikolova, Antoine Italiano, E. Filvaroff, M. Vieito Villar
Rok vydání:	2020
Předmět:	Oncology BET inhibitor medicine.medical_specialty business.industry Internal medicine Relapsed refractory medicine Hodgkin lymphoma In patient Hematology business Phase i study
Zdroj:	Annals of Oncology. 31:S5
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.01.025
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::88d79aff59bada26f44113db50e9b264 https://doi.org/10.1016/j.annonc.2020.01.025 Zobrazit plný text záznamu